The Anglo-Swedish drugmaker’s flirtation with a grand combo with US group Bristol Myers Squibb is baffling AstraZeneca shares fall 8.9% over merger talks with US cancer drug firm Sir Pascal Soriot, chief executive of AstraZeneca, starts with huge credit in the bank, obviously. His long tenure has been a triumph, starting with the against-the-odds victory over Pfizer’s charmless accountants in 2014. The $39bn (£29bn) purchase of Alexion in 2021 looked a little over-priced at the time, but you could see how it sat well with Soriot’s sermons on the importance of backing science. The deal got AZ into the field of medicines for rare diseases, which should offer decades of growth. A flirtation with a grand combo with US group Bristol Myers Squibb (BMS), by contrast, looks baffling. What’s the big idea here? Why bet the farm on a $400bn (£300bn) mega-merger? The first challenge would be how to rip out a few billions-worth of costs to justify the takeover premium. Soriot has normally viewed such corporate exercises as anti-patient. And why do it now? In the absence of a statement by AZ – not even to confirm the basic accuracy of the FT’s initial report of talks with BMS – o
Aug 3, 2026 → Aug 3, 2026
The Anglo-Swedish drugmaker’s flirtation with a grand combo with US group Bristol Myers Squibb is baffling AstraZeneca shares fall 8.9% over merger talks with US cancer drug firm Sir Pascal Soriot, chief executive of AstraZeneca, starts…
Read original at The Guardian →1 updates from 1 source.
The Anglo-Swedish drugmaker’s flirtation with a grand combo with US group Bristol Myers Squibb is baffling AstraZeneca shares fall 8.9% over merger talks with US cancer drug firm Sir Pascal Soriot, chief executive of…
Read original at The Guardian →What this story stands on. Tier 0 is a primary record or the subject's own words; higher tiers must be attributed, never stated as bare fact.
The Anglo-Swedish drugmaker’s flirtation with a grand combo with US group Bristol Myers Squibb is baffling AstraZeneca shares fall 8.9% over merger talks with US cancer drug firm Sir Pascal Soriot, chief executive of AstraZeneca, starts…
View source →Tier key: T0 = Primary source · T1 = Wire · T2 = Outlet report · T3 = Commentary
Deal value fell 10% year over year in the third quarter after a strong first half, when global M&A was up nearly 50% and included 47 deals worth at least $10 billion. Ted Smith,…
Triptorelin, already listed for prostate cancer, should have unrestricted use, the Pharmaceutical Benefits Advisory Committee says Follow our Australia news live blog for latest…
With wildfires blazing and temperatures hitting record highs in Europe, one China-made product has never been hotter: air-conditioners. Europeans, who have been slower to adopt AC…
In an SEC filing, EA said that as of today, it had obtained “all regulatory approvals required to complete the Merger.” The deal, announced in September, is expected to close “on…
New York City is counting on office-to-apartment conversions to help relieve its housing shortage. But after structural problems earlier this month threatened a partial collapse…
